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Fluoroquinolones and risk of Achilles tendon disorders:
case›control study
P D van der Linden, M C J M Sturkenboom, R M C Herings, H G M Leufkens, B H Ch Stricker
Fluoroquinolones have been associated with tendon
disorders, usually during the first month of
treatment,1–5 but the epidemiological evidence is scanty.
We did a nested case›control study among users of
fluoroquinolones in a large UK general practice
database to study the association with Achilles tendon
disorders.
Participants, methods, and results
We obtained data from the IMS Health database (UK
MediPlus), which contains data from general practice
on consultations, morbidity, prescriptions, and other
interventions in a source population of 1›2 million
inhabitants. The base cohort consisted of all patients
aged 18 years or over who had received a
fluoroquinolone. We excluded people with a history of
Achilles tendon disorders, cancer, AIDS, illicit drug
use, or alcohol misuse. We identified potential cases by
reviewing patient profiles and clinical data and
excluded tendon disorders due to direct trauma. We
randomly sampled a group of 10 000 control patients
from the study cohort.
We defined four categories of exposure to
fluoroquinolones: current use, recent use, past use, and
no use. We defined current use as when the tendon dis›
order occurred in the period between the start of the
fluoroquinolone treatment and the calculated end date
plus 30 days, recent use as when the calculated end
date was between 30 and 90 days before the
occurrence of the disorder, and past use as when the
calculated end date was more than 90 days before the
occurrence of the disorder. We used unconditional
logistic regression analysis to calculate adjusted relative
risks and 95% confidence intervals for Achilles tendon
disorders, using the no use group as the reference. We
adjusted for age, sex, number of visits to the general
practitioner, use of corticosteroid, calendar year, obes›
ity, and history of musculoskeletal disorders.
The cohort included 46 776 users of fluoroqui›
nolones between 1 July 1992 and 30 June 30 1998, of
whom 704 had Achilles tendinitis and 38 had Achilles
tendon rupture. Four hundred and fifty three (61%) of
the cases were women, and the mean age was 56 years.
Cases visited the general practitioner significantly
more often than did controls (mean 20 v 17). Cases
and controls were similar with respect to indications
for use of fluoroquinolone. Age, number of visits to the
general practitioner in the previous 18 months, gout,
obesity, and use of corticosteroid were determinants of
Achilles tendon disorders. The adjusted relative risk of
Achilles tendon disorders with current use of
fluoroquinolones was 1.9 (95% confidence interval 1.3
to 2.6). The risk for recent and past use was similar to
that for no use. The relative risk with current use was
3.2 (2.1 to 4.9) among patients aged 60 and over and
0.9 (0.5 to 1.6) among patients aged under 60 (table). In
patients aged 60 or over, concurrent use of
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corticosteroids and fluoroquinolones increased the
risk to 6.2 (3.0 to 12.8).
Comment
Current exposure to fluoroquinolones increases the
risk of Achilles tendon disorders. This finding is in
agreement with a smaller study, in which we found an
association between tendinitis and fluoroquinolones.5
Our results indicate that this adverse effect is relatively
rare, with an overall excess risk of 3.2 cases per 1000
patient years. The effect seems to be restricted to
people aged 60 or over, and within this group
concomitant use of corticosteroids increased the risk
substantially. The proportion of Achilles tendon disor›
ders among patients with both risk factors that is
attributable to their interaction was 87%. Although the
mechanism is unknown, the sudden onset of some
tendinopathies, occasionally after a single dose of a
fluoroquinolone, suggests a direct toxic effect on colla›
gen fibres. Prescribers should be aware of this risk,
especially in elderly people taking corticosteroids.
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Relative risk of Achilles tendon disorders associated with use of fluoroquinolones
according to age
Cases Controls
Crude relative risk
(95% CI)
Adjusted relative risk
(95% CI)*
All Achilles tendon disorders
Age <60: (n=423) (n=6058)
No use 308 4387 1.0 1.0
Current use 13 174 1.1 (0.6 to 1.9) 0.9 (0.5 to 1.6)
Recent use 19 240 1.1 (0.7 to 1.8) 1.0 (0.6 to 1.7)
Past use 83 1257 0.9 (0.7 to 1.2) 0.9 (0.7 to 1.1)
Age >60: (n=319) (n=3942)
No use 211 2797 1.0 1.0
Current use 33 124 3.5 (2.3 to 5.3) 3.2 (2.1 to 4.9)
Recent use 15 182 1.1 (0.6 to 1.9) 1.0 (0.6 to 1.7)
Past use 60 839 0.9 (0.7 to 1.3) 0.8 (0.6 to 1.1)
Achilles tendon ruptures
Age <60: (n=21) (n=6058)
No use 18 4387 1.0 1.0
Current use — 174 — —
Recent use — 240 — —
Past use 3 1257 0.6 (0.2 to 2.0) 0.6 (0.2 to 2.0)
Age >60: (n=17) (n=3942)
No use 8 2797 1.0 1.0
Current use 3 124 8.4 (2.2 to 32.2) 7.1 (1.7 to 29.1)
Recent use 2 182 3.8 (0.8 to 18.2) 3.5 (0.7 to 17.3)
Past use 4 839 1.7 (0.5 to 5.5) 1.4 (0.4 to 4.8)
Achilles tendinitis
Age <60: (n=402) (n=6058)
No use 290 4387 1.0 1.0
Current use 13 174 1.1 (0.6 to 2.0) 1.0 (0.5 to 1.8)
Recent use 19 240 1.2 (0.7 to 1.9) 1.1 (0.7 to 1.8)
Past use 80 1257 1.0 (0.7 to 1.2) 0.9 (0.7 to 1.2)
Age >60: (n=302) (n=3942)
No use 203 2797 1.0 1.0
Current use 30 124 3.3 (2.2 to 5.1) 3.1 (2.0 to 4.8)
Recent use 13 182 1.0 (0.6 to 1.8) 0.9 (0.5 to 1.6)
Past use 56 839 0.9 (0.7 to 1.2) 0.8 (0.6 to 1.1)
*Adjusted for sex, age, visits to general practitioner, calendar year, use of corticosteroid, history of
musculoskeletal disorders, and obesity.
The surname I do not have
I come from the south of India—Chennai in Tamil Nadu—and am
currently working as a senior house officer in the NHS. I am
writing this article to address the problem of surnames facing
several Tamil doctors abroad. My name (one and only name) is
Radhika. Until I got married, I was called M Radhika. The initial
usually denotes the first letter of your father’s name or native
place—in my case it was the first letter of my father’s name,
Murugesan(his one and only name).After I was married, I became
Radhika Ramkumar, which was fine.
When I came to Britain I was asked to give my surname
wherever I went, but there is no concept of surnames in Tamil
Nadu. Not knowing what to do, I gave my husband’s name as my
surname: he, in fact, uses his father’s name as his first name and
his own name as his surname (I later found out this is a common
practice among Tamil doctors). Everything was fine until people
started calling me Dr Ramkumar, which is really my husband’s
name. Back home, I would have been Dr Radhika to patients, or
possibly Dr Radhika Ramkumar, but definitely not Dr Ramkumar.
I did some research on this subject. In every other state in
India, people have surnames, so they don’t have a problem. In
Tamil Nadu in the olden days people added their caste names
(such as Pillai, Mudaliar, Iyer, etc), which served as “surnames.”
However, this has been given up by most people (for the best,
since there may be up to 50 Pillais in one area of Chennai).
I am at a loss at what to do. Do I have to take up my caste name
(which will rekindle the old flames of the caste system among
non›resident Indians) or just refuse to give a surname? A name is
a very personal thing, and I just cannot accept being called Dr
Ramkumar. I welcome comments on this issue from doctors
facing similar problems.
Radhika (Ramkumar?) senior house officer (psychiatry), St Clement’s
Hospital, Ipswich
radish75@hotmail.com
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